bisnafide has been researched along with B16 Melanoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behrens, CH; Behrens, DL; Chen, SF; Fredericks, JR; Kirshenbaum, MR; Papp, LM; Polkus, ST; Sipple, P; Stafford, MM; Sun, JH | 1 |
1 other study(ies) available for bisnafide and B16 Melanoma
| Article | Year |
|---|---|
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Colonic Neoplasms; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Isoquinolines; KB Cells; Kinetics; Leucine; Leukemia L1210; Leukemia P388; Mammary Neoplasms, Experimental; Melanoma; Melanoma, Experimental; Mesylates; Mice; Mitoxantrone; Thymidine; Transplantation, Heterologous; Tumor Cells, Cultured; Uridine | 1994 |